Clinical Trial IDNCT04309500
Lead SponsorUniversity of Michigan
Principal Investigator
Start Date2020-06-01
Completion Date2021-01-01
Study TypeInterventional
StatusNot yet recruiting


The goal of this study is to test efficacy and safety of person-centered, culturally-informed protocols for disclosure of different combinations of Alzheimer's dementia risk factors. Building on the results from a federally-funded assessment of preferences and needs of racially diverse participants and their respective friends/family members, in regard to Dementia - Alzheimer's Type, we have produced protocols for communication of DAT risk, with attention to specific adaptations in style or content based on individual factors and preferences. These protocols allow for communication of risk based on clinical history and diagnosis, structural neuroimaging, apolipoprotein-E status, and amyloid and tau burden on positron emission tomography. In particular, protocols specify (a) effective methods of communicating risk conferred by each data source, (b) information designed for patients versus informants, (c) psychoeducation needs, and (d) resource/support needs. We will recruit a randomly-selected subset of 10 dyads (including 5 participants who are Non-Hispanic African-American, 5 participants who are Non-Hispanic White) from the Stage I sample to whom we will develop and implement personalized DAT risk disclosure protocols. We will provide preliminary information on the effectiveness of these protocols in terms of patient/co-participant comprehension and recall of feedback provided, satisfaction with the content and format of feedback, and initial changes in mood or behavior immediately following and shortly after risk disclosure sessions.


Mild Cognitive Impairment, Healthy AgingBehavioral: Personalized DAT Risk Disclosure ProtocolN/A


AgeGenderAccepts Healthy Volunteers
65 Years and older.AllAccepts Healthy Volunteers